|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBA5 |
Gene summary for UBA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBA5 | Gene ID | 79876 |
| Gene name | ubiquitin like modifier activating enzyme 5 | |
| Gene Alias | DEE44 | |
| Cytomap | 3q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0002262 | UniProtAcc | Q9GZZ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79876 | UBA5 | LZE2T | Human | Esophagus | ESCC | 3.68e-06 | 7.71e-01 | 0.082 |
| 79876 | UBA5 | LZE4T | Human | Esophagus | ESCC | 1.82e-16 | 4.13e-01 | 0.0811 |
| 79876 | UBA5 | LZE7T | Human | Esophagus | ESCC | 6.77e-06 | 5.88e-01 | 0.0667 |
| 79876 | UBA5 | LZE8T | Human | Esophagus | ESCC | 6.14e-10 | 2.32e-01 | 0.067 |
| 79876 | UBA5 | LZE24T | Human | Esophagus | ESCC | 3.76e-17 | 3.82e-01 | 0.0596 |
| 79876 | UBA5 | LZE6T | Human | Esophagus | ESCC | 1.69e-06 | 4.31e-01 | 0.0845 |
| 79876 | UBA5 | P1T-E | Human | Esophagus | ESCC | 2.32e-08 | 4.85e-01 | 0.0875 |
| 79876 | UBA5 | P2T-E | Human | Esophagus | ESCC | 2.24e-57 | 9.65e-01 | 0.1177 |
| 79876 | UBA5 | P4T-E | Human | Esophagus | ESCC | 2.11e-30 | 8.77e-01 | 0.1323 |
| 79876 | UBA5 | P5T-E | Human | Esophagus | ESCC | 2.68e-16 | 4.38e-01 | 0.1327 |
| 79876 | UBA5 | P8T-E | Human | Esophagus | ESCC | 3.77e-22 | 4.64e-01 | 0.0889 |
| 79876 | UBA5 | P9T-E | Human | Esophagus | ESCC | 3.01e-17 | 4.67e-01 | 0.1131 |
| 79876 | UBA5 | P10T-E | Human | Esophagus | ESCC | 4.45e-36 | 6.70e-01 | 0.116 |
| 79876 | UBA5 | P11T-E | Human | Esophagus | ESCC | 3.27e-11 | 5.00e-01 | 0.1426 |
| 79876 | UBA5 | P12T-E | Human | Esophagus | ESCC | 5.15e-27 | 4.01e-01 | 0.1122 |
| 79876 | UBA5 | P15T-E | Human | Esophagus | ESCC | 3.55e-28 | 6.63e-01 | 0.1149 |
| 79876 | UBA5 | P16T-E | Human | Esophagus | ESCC | 7.47e-38 | 7.05e-01 | 0.1153 |
| 79876 | UBA5 | P17T-E | Human | Esophagus | ESCC | 6.76e-13 | 3.30e-01 | 0.1278 |
| 79876 | UBA5 | P19T-E | Human | Esophagus | ESCC | 1.73e-02 | 6.12e-01 | 0.1662 |
| 79876 | UBA5 | P20T-E | Human | Esophagus | ESCC | 2.24e-16 | 2.73e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00096363 | Colorectum | FAP | response to toxic substance | 53/2622 | 262/18723 | 3.35e-03 | 2.46e-02 | 53 |
| GO:00021815 | Colorectum | CRC | cytoplasmic translation | 70/2078 | 148/18723 | 1.53e-28 | 9.16e-25 | 70 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:000963610 | Endometrium | AEH | response to toxic substance | 52/2100 | 262/18723 | 2.89e-05 | 5.40e-04 | 52 |
| GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
| GO:000963615 | Endometrium | EEC | response to toxic substance | 54/2168 | 262/18723 | 1.65e-05 | 3.18e-04 | 54 |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:190300816 | Esophagus | ESCC | organelle disassembly | 89/8552 | 114/18723 | 1.36e-12 | 5.80e-11 | 89 |
| GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
| GO:0002262111 | Esophagus | ESCC | myeloid cell homeostasis | 104/8552 | 157/18723 | 1.49e-07 | 2.36e-06 | 104 |
| GO:0034101111 | Esophagus | ESCC | erythrocyte homeostasis | 88/8552 | 129/18723 | 1.81e-07 | 2.84e-06 | 88 |
| GO:0071383110 | Esophagus | ESCC | cellular response to steroid hormone stimulus | 127/8552 | 204/18723 | 1.26e-06 | 1.55e-05 | 127 |
| GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
| GO:0030218111 | Esophagus | ESCC | erythrocyte differentiation | 80/8552 | 120/18723 | 2.69e-06 | 3.08e-05 | 80 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBA5 | SNV | Missense_Mutation | rs368103311 | c.563N>A | p.Arg188Gln | p.R188Q | Q9GZZ9 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| UBA5 | SNV | Missense_Mutation | c.50G>A | p.Arg17Gln | p.R17Q | Q9GZZ9 | protein_coding | tolerated(0.57) | benign(0) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| UBA5 | SNV | Missense_Mutation | novel | c.136N>A | p.Glu46Lys | p.E46K | Q9GZZ9 | protein_coding | deleterious(0.01) | benign(0.356) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| UBA5 | SNV | Missense_Mutation | rs150313260 | c.215N>A | p.Arg72His | p.R72H | Q9GZZ9 | protein_coding | deleterious(0.02) | probably_damaging(0.912) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| UBA5 | SNV | Missense_Mutation | c.614N>A | p.Ser205Tyr | p.S205Y | Q9GZZ9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD | |
| UBA5 | SNV | Missense_Mutation | rs143516396 | c.182N>A | p.Arg61Gln | p.R61Q | Q9GZZ9 | protein_coding | deleterious(0.01) | benign(0.125) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UBA5 | SNV | Missense_Mutation | rs61748106 | c.199N>A | p.Asp67Asn | p.D67N | Q9GZZ9 | protein_coding | tolerated(1) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| UBA5 | SNV | Missense_Mutation | c.66G>T | p.Glu22Asp | p.E22D | Q9GZZ9 | protein_coding | tolerated(0.41) | benign(0.021) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| UBA5 | SNV | Missense_Mutation | novel | c.436N>A | p.Val146Ile | p.V146I | Q9GZZ9 | protein_coding | tolerated(0.23) | benign(0) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| UBA5 | SNV | Missense_Mutation | novel | c.1036N>T | p.Val346Leu | p.V346L | Q9GZZ9 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |